Faruqi & Faruqi, LLP Investigates Baxter International Investor Claims: Deadline Approaches

Faruqi & Faruqi, LLP Investigates Investor Claims Against Baxter International

In a recent announcement, Faruqi & Faruqi, LLP, a distinguished national securities law firm, is urging investors who incurred losses due to Baxter International Inc. (NYSE: BAX) to come forward. This initiative marks an important moment for stockholders of Baxter who acquired shares between February 23, 2022, and July 30, 2025. The firm has opened channels for investors to discuss their legal rights and potential claims while emphasizing a crucial deadline of December 15, 2025, for those interested in taking a lead role in a federal securities class action lawsuit against the company.

Nature of the Claims Against Baxter International

The complaints against Baxter allege that the company and its executives violated federal securities regulations by presenting misleading information and neglecting to disclose critical facts regarding the Novum LVP (Large Volume Pump). Reports indicate that the device experienced systemic failures, including under-infusion, over-infusion, and total failure to deliver fluids, thereby posing serious health risks to patients. This situation has not only endangered lives but has also raised substantial concerns about the integrity of Baxter's product safety protocols.

Investors are encouraged to take note of the specific allegations, which include:
1. Systemic Defects: Claims indicate that the Novum LVP was known to have systemic defects that resulted in dangerous malfunctions.
2. Notification of Malfunctions: A failure to adequately inform stakeholders of device malfunctions resulting in injuries and fatalities.
3. Inadequate Remedial Measures: Baxter's attempts to rectify the issues were deemed insufficient, as serious design flaws persisted.
4. Sales Impact: The risk of significant sales disruptions as customers were encouraged to halt the use of existing Novum LVPs, leading to a complete pause on new sales.
5. Materially False Statements: Baxter allegedly made false and misleading statements regarding the safety, efficacy, and market viability of the Novum LVPs.

Impact of Recent Developments

The gravity of the situation became apparent on July 31, 2025, when Baxter announced a voluntary and temporary halt to shipments and planned installations of the Novum LVP. Following this announcement, Baxter's stock price plummeted by 22.4%, closing at $21.76. This drastic decline underscores the urgency and importance of the ongoing investigation by Faruqi & Faruqi, as investors who experienced financial losses are encouraged to take immediate action.

Call to Action

Faruqi & Faruqi, LLP is actively seeking individuals potentially affected by Baxter's practices to reach out for guidance. The law firm highlights that potential lead plaintiffs should possess significant financial interests in the outcome of the class action lawsuit. Investors who wish to participate should consider contacting Josh Wilson of Faruqi & Faruqi for personal consultation.

To learn more about the ongoing investigation and your rights as a Baxter investor, you can visit their website at www.faruqilaw.com/BAX or call Josh Wilson directly at 877-247-4292. This investigation represents not only a chance for financial recovery but serves as a reminder about the accountability of healthcare corporations.

By understanding the allegations against Baxter and acting within the provided time frame, investors may safeguard their interests. Moreover, Faruqi & Faruqi continues to welcome information from whistleblowers, former employees, and shareholders about Baxter's operational practices. As this situation unfolds, staying informed and proactive will be key for those targeted by the alleged malpractice.